In acute promyelocytic leukemia, granulocytic differentiation is arrested at the promyelocyte stage. The variant t(11;17) translocation produces two fusion proteins, promyelocytic leukemia zinc finger-retinoic acid receptor α (PLZF-RARα) and RARα-PLZF, both of which participate in leukemia development. Here we provide evidence that the activity of CCAAT/enhancer binding protein α (C/EBPα), a master regulator of granulocytic differentiation, is severely impaired in leukemic promyelocytes with the t(11;17) translocation compared with those associated with the t(15;17) translocation. We show that RARα-PLZF inhibits myeloid cell differentiation through interactions with C/EBPα tethered to DNA, using ChIP and DNA capture assays. Furthermore, RARα-PLZF recruits HDAC1 and causes histone H3 deacetylation at C/EBPα target loci, thereby decreasing the expression of C/EBPα target genes. In line with these results, HDAC inhibitors restore in part C/EBPα target gene expression. These findings provide molecular evidence for a mechanism through which RARα-PLZF acts as a modifier oncogene that subverts differentiation in the granulocytic lineage by associating with C/EBPα and inhibiting its activity.
RARα, i.e., chronic myeloid leukemia (CML) (11) , into APL (12) . Moreover, the presence of RARα-PLZF increases the proliferation and resistance to RA treatment in double transgenic mice (12) . At the molecular level, RARα-PLZF binds to DNA via the PLZF binding site and derepresses PLZF target genes such as cyclin A, Hoxb2a and c-Myc (13) (14) (15) , thereby causing increased proliferation. In addition, RA resistance has been associated with an up-regulation of cellular retinoic acid binding protein 1 (CRABPI) (16) , although additional mechanisms could also contribute to this resistance. Furthermore, how RARα-PLZF modifies the tumor phenotype remains to be clarified.
Somatic mutations in genes encoding lineage-restricted transcription regulators were identified in cytogenetically normal acute myeloblastic leukemias (AML) (17, 18) , supporting the view that disruption of lineage regulatory mechanisms is an important event in leukemogenesis. C/EBPα is a member of the basic regionleucine zipper (bZIP) family of transcription factors which is important for hematopoietic stem cells and for differentiation in the granulocytic lineage (19, 20) . In human AML, C/EBPα function and activity are frequently disrupted via several mechanisms: dominantnegative point mutations (17) , transcriptional inhibition by oncoproteins [acute myeloid leukemia 1-eight twenty one (AML1-ETO), myelodysplasia syndrome associated protein 1-ecotropic virus integration site 1 (AML1-MDS1-EVI1), and core binding factor, beta subunit-myosin heavy chain 11 (CBFB-MYH11)], or promoter hypermethylation (reviewed in refs. 18 and 19) .
In the present study, we aim to define the cellular and molecular anomalies induced by RARα-PLZF, using the model cell line 32D, primary fetal liver cells, and primary leukemic cells from APL patients with t(11;17) or t (15;17) translocations. We show that RARα-PLZF recruits HDAC1 and severely impairs C/EBPα function, thereby contributing to differentiation arrest in APL.
Results
RARα-PLZF Impairs G-CSF-Induced Survival. To define the role of RARα−PLZF in the myeloid lineage, we ectopically expressed the fusion gene in 32D myeloid cells. This cell line was chosen because it retains two essential properties of primary myeloid cells: growth factor requirements for survival and terminal granulocytic differentiation in response to G-CSF (Fig. S1A ). In the presence of IL-3, the cells self-propagate and remain undifferentiated whereas G-CSF-induced typical granulocyte differentiation, Gr-1 surface expression, and Csf3r up-regulation ( Fig. S1 B and C) , reproducing the pattern of differentiation in primary myeloid cells, whereby Csf3r expression also increased as the cells progress from the immature myeloid stage (CD11b (Fig. S1D) . We generated several independent 32D clones expressing the RARα-PLZF (RP3, RP7, and RP11) or the PLZF-RARα (PR1 and PR2) fusion genes (Fig. 1B) . All clones survived and proliferated in the presence of IL-3 ( Fig. 1C) and were apoptotic after 24 h of growth factor withdrawal (Fig. 1C) . Surprisingly, G-CSF failed to suppress apoptosis in RARα-PLZF-expressing cells which showed elevated apoptosis whereas parental 32D and PLZF-RARα -expressing cells (Fig. 1C and Fig. S2A ) responded to G-CSF treatment.
The induction of STAT DNA binding activity is an early event in cytokine signaling (21) . Compared with control cells, G-CSFinduced STAT activity, assessed by electromobility shift assay, was impaired in RP7 and RP11 cells and was reduced in RP3 cells, indicating that the defective survival/differentiation response to G-CSF is upstream of Janus kinase-STAT (JAK-STAT), possibly occurring at the receptor level (Fig. S2B ).
RARα-PLZF Decreases Expression of CSF3R. Csf3r mRNA expression levels in RP7, RP11, and in five clones expressing RARα-PLZF fused to the tag for tandem affinity purification (RP-TAP15, 19, 23, 24, 33) as well as RP-HA were less than 20% that of parental 32D cells by Northern blotting and/or quantitative RT-PCR analysis ( Fig. 1 D and E) . In contrast, PLZF-RARα expression did not affect Csf3r mRNA levels (Fig. 1D) . Furthermore, RP3 cells that showed a partial response to G-CSF also exhibited a partial reduction of Csf3r mRNA (Fig. 1D) . Therefore, Csf3r expression levels concurred with the biological assay and indicated that RARα-PLZF, but not PLZF-RARα, inhibits Csf3r gene expression in 32D myeloid cells (Fig. 1D) .
To assess whether Csf3r is indeed downstream of RARα-PLZF, we performed a rescue experiment by ectopically expressing CSF3R in RP cells. Because G-CSF is not species-specific, we delivered the human CSF3R gene to distinguish the transgene from the endogenous gene (Fig. 1F , Upper, RNA levels; Fig. 1F , Lower, protein levels). In clone RP7 expressing hCSF3R, cell survival in response to G-CSF was restored for a 24 h period whereas control RP7 cells (empty vector) as well as parental RP7 cells underwent apoptosis ( Fig. 1G and Fig. S2D) . However, the survival of RP7 rescued by hCSF3R could not be sustained for longer periods in G-CSF-containing medium (Fig. 1G, Upper) , whereas parental 32D cells continued to survive and proliferate in response to G-CSF. As expected, all cells survived and proliferated in IL-3 control cultures, consistent with the specificity of RARα-PLZF for the CSF3R pathway (Fig. 1G, Bottom) .
These results suggest that RARα-PLZF is upstream of Csf3r. Nonetheless, the inability of cells rescued with hCSF3R to survive beyond 2 d in G-CSF medium suggests additional defects due to the presence of RARα-PLZF. Cell death was not due to early differentiation, as assessed by morphological analysis (Fig. S2D) . Next, we assessed whether CSF3R expression is impaired in primary murine fetal liver cells expressing RARα-PLZF and in leukemic cells from APL patients. To rule out the possibility that differences in gene expression could be due to an imbalance in cell populations induced by the transgene in primary murine hematopoietic cells, we purified CD11b + cells after retroviral gene transduction (Fig. S3 ). Ectopic expression of RARα-PLZF resulted in a twofold repression of Csf3r mRNA levels in CD11b
+ fetal liver cells compared with control cells (empty vector) (Fig. 1H) . Furthermore, high levels of CSF3R mRNA were detected by RT-PCR in three APL samples with the t(15;17) translocation, comparable to those expressed in primary bone marrow cells from three healthy donors (Fig. 1I) . In contrast, CSF3R transcripts were low in two t(11;17) APL patient samples (Fig. 1I) . Therefore, RARα-PLZF expression correlates with impaired CSF3R expression in leukemic promyelocytes.
RARα-PLZF Decreases the Expression of C/EBPα Target Genes Without
Affecting C/EBPα Levels. C/EBPα is important for optimal Csf3r expression in vivo (22) , although the induction of granulocytic differentiation by C/EBPα could be Csf3r-independent (23). Therefore, we analyzed the expression levels of additional C/EBPα target genes that are involved in myeloid differentiation, i.e., Ltf, Mpo, Ela2 as well as miR-223 (24) (25) (26) (27) , all produced at the promyelocyte stage of differentiation. Interestingly, these C/EBPα target genes were strongly reduced in RP7, RP11, and RP-TAP19 clones compared with parental cells or control cells expressing the empty TAP vector ( Fig. 2A ) and in RP7 ectopically expressing hGCSFR upon G-CSF stimulation (Fig. 2B) . Decreased C/EBPα target genes were not due to decreased C/EBPα protein levels compared with control cells (Fig. 2C ). In addition, we monitored RARα protein levels and found little clonal variation (Fig. 2C) . Together, our results indicate that RARα−PLZF acts in parallel to or downstream of C/EBPα.
We next verified the relative expression levels of RARα-PLZF to C/EBPα in our clones and compared this to the ratio observed in primary APL samples. To this end, we designed a semiquantitative Western blot analysis for C/EBPα and for RARα-PLZF (Fig. S4 ), using a single purified recombinant protein of known concentration. Briefly, we used purified JUN as a standard to determine the concentrations of HA-or TAP-tagged JUN in transfected cell extracts with an antibody against JUN (Fig. S4A) . Then the concentrations of HA-or TAP-tagged proteins of interest (HA-C/ EBPα, RP-TAP, or HA-PR), determined using JUN-HA or JUN-TAP as standards (Fig. S4 B, C , and E), served to estimate the concentrations of endogenous C/EBPα (Fig. S4C ) and transfected RARα-PLZF (Fig. S4D) or PLZF (Fig. S4E ) in our clones as well as of endogenous RARα (Fig. S4F ) in patient samples.
C/EBPα protein levels were comparable in cells expressing RARα-PLZF and control cells, i.e., in the range of ∼1600-2200 molecules per cell (Fig. 2D) . Next, we compared the ratio of RARα-PLZF to C/EBPα in our RP clones and found a molecular ratio of 0.3-0.9 (Fig. 2D) . We compared these results in primary APL samples. Due to the scarcity of the t(11;17) translocation, we used two t(15;17) APL samples, with the assumption that expression levels driven from the endogenous RARα promoter in these two translocations, i.e., RARa and RARα-PLZF, would be comparable (Fig. 2D) . The ratio of RARα to C/EBPα in two primary t(15;17) APL samples was 0.3 and 0.8, respectively (Fig. 2D) . Thus, the levels of expression of our constructs compared with C/EBPα levels are reminiscent of the ratio between RARα and C/EBPα in t(15;17) APL patients, confirming the validity of our model.
RARα-PLZF Occupies C/EBPα Target Loci. Our results so far indicate that RARα-PLZF inhibits the expression of C/EBPα target genes without affecting C/EBPα expression levels. We therefore tested the possibility that RARα-PLZF directly inhibits C/EBPα transcriptional activity. We first assessed C/EBPα activity in myeloid cells using the CSF3R promoter reporter (22) . The CSF3R promoter is active in 32D cells (Fig. S5A) , and this activity was not affected by the empty MSCV vector (control) (Fig. 3A) . However, CSF3R promoter activity was consistently repressed by RARα-PLZF (two-to threefold) and PLZF but not by PLZF-RARα (Fig. 3A) . Moreover, RARα-PLZF did not inhibit the activity of the promoterless reporter vector pXPII (Fig. S5A) , indicating that RARα-PLZFdependent repression was specific to CSF3R promoter sequences.
We located the essential contribution of the C/EBPα binding site at position −49 of the CSF3R promoter (22) (Fig. S5A) which is required for promoter activity in 32D cells (Fig. 3B ) and for transcriptional repression by PLZF and RARα-PLZF in these cells (Fig.  S5A) . In addition, RARα-PLZF did not inhibit C/EBPα DNA binding by gel shift assay (Fig. S5B, lanes 1 and 6) nor C/EBPα occupancy of its target loci by ChIP using an anti-C/EBPα antibody (Fig. 3C) . Finally, RARα-PLZF and C/EBPα cooccupied the promoters of all five C/EBPα target genes tested in Fig. 1E (Fig. 3 C and  D) , which were two-to sixfold higher in chromatin extracts immunoprecipitated with anti-TAP (RP-TAP 19, Fig. 3D ) or with anti-RARα (RP7, Fig. S5C ) compared with their respective controls (TAP or 32D). Of note, myeloid promoter sequences were less than twofold enriched in control TAP cells compared with control immunoglobulins and irrelevant promoter sequences (Kit) (Fig. 3D,  Left) , confirming the specificity of the ChIP, whereas all myeloid promoters were 5-to 25-fold enriched in anti-RARα-immunoprecipitated chromatin extracts in 32D cells, suggesting that RARα and C/EBPα may coregulate target genes. Because transcription repression by RARα-PLZF requires the integrity of the C/EBPα binding site (Fig. 3B) , our data indicate that RARα-PLZF inhibits the transcriptional activity of C/EBPα tethered to its cognate binding sites on target promoters. recruits RARα-PLZF or PLZF to DNA (28). The above results led us to address the question whether C/EBPα actually recruits RARα-PLZF to target promoters. To this end, we designed a DNA capture assay (29) in which the −74 to +67 region of the Csf3r promoter was immobilized on magnetic beads and incubated with nuclear extracts from C/EBPα− and control TAP-or RP-TAP-expressing cells (Fig.  3E ). Csf3r promoter sequences recruited both C/EBPα and RARα-PLZF, consistent with the ChIP assay, and both associations required the integrity of the C/EBP binding site (Fig. 3E, lanes 2 and  4) . Together, these observations raise the possibility that RARα-PLZF is recruited to DNA by interaction with C/EBPα and inhibits its transcriptional activity, an issue that we addressed using in vitro and in vivo protein-protein binding assays. In GST-pull-down assays, in vitro translated RARα-PLZF and PLZF specifically interacted with GST-C/EBPα whereas PLZF-RARα did not (Fig. 4A) , consistent with their respective capacities to inhibit or not CSF3R promoter activity in 32D cells (Fig.  3A) . Furthermore, the seven C-terminal zinc fingers of PLZF were sufficient for this association (Fig. 4A) . The interaction between RARα-PLZF and C/EBPα was further confirmed by coimmunoprecipitation using in vitro translated radiolabeled proteins (Fig. S6A) . The antibody against C/EBPα brought down RARα-PLZF whereas a control preimmune rabbit serum did not. This interaction also occurred in vivo with endogenous C/EBPα, as observed by coimmunoprecipitation of HA-tagged RARα-PLZF with an anti-C/EBPα antibody using 32D nuclear extracts (Fig. 4B) . The absence of coimmunoprecipitation in parental 32D cells confirmed the specificity of the procedure.
PLZF recruits histone deacetylase complexes via its C-terminal zinc fingers to repress transcription (30, 31) . Here we show that RARα-PLZF interacts with HDAC1 in vitro (Fig. 4C) . Moreover, HDAC1 coimmunoprecipitated with C/EBPα in RARα-PLZF transfectants but not in parental 32D cells (Fig. 4D , compare lanes 2 and 5) and was twofold enriched in immunoprecipitated chromatin from 32D RP7 cells compared with 32D control cells (Fig. 4E) . This was reproducibly and specifically associated with a reduction in histone H3 acetylation at all of the C/EBPα target promoters (Fig. 4F) . The absence of histone H3 acetylation at the Kit promoter in these cells correlated with the absence of Kit expression and confirmed the specificity of the ChIP procedure. In addition, inhibition of histone deacetylase activity with trichostatin A (TSA) induced a three-to fourfold increase in Csf3r mRNA levels in clone RP7, while not affecting parental 32D cells (Fig. 4G) , concurring with the view that transcription repression by RARα-PLZF involves a histone deacetylase activity. Moreover, TSA treatment reversed the repression of the CSF3R proximal promoter in 32D cells by RARα-PLZF in transcription assays, without affecting the activity of the promoter alone (Fig. S6B) . Whereas TSA was fully efficient in transient assays with luciferase reporters (Fig. S6B) , the expression of the endogenous Csf3r gene was only partially rescued by TSA (Fig. 4G) . This difference is currently not known but could possibly be due to more complex regulatory mechanisms in situ. We therefore conclude that transcription inhibition by RARα-PLZF is sensitive to the HDAC inhibitor TSA.
Together, our data support a model where RARα-PLZF is recruited on C/EBP consensus sequences by its ability to physically interact with C/EBPα, resulting in HDAC1 recruitment, histone H3 hypoacetylation, and decreased expression of C/EBPα target genes (Fig. 4H) .
Discussion
In the present study, we provide evidence for a unique role of RARα-PLZF in APL, via direct interaction with and inhibition of C/EBPα activity.
C/EBPα is a master regulator of granulocytic differentiation. Decreased C/EBPα transcription, translation, or loss of function mutations is commonly observed in AML (mostly M1, M2, and M4), in familial AML with variable morphology (M1, M2-Eo, and M4-Eo), as well as in CML (reviewed by ref. 18) . We now define a distinct mechanism of inhibition of C/EBPα transcriptional RARα-PLZF, which is always present in t(11;17) APL, derepresses PLZF target genes involved in cell proliferation. Whereas this may explain deregulated cell proliferation, RARα−PLZF also causes differentiation arrest and modifies the phenotype of the disease induced by PLZF-RARα in transgenic mice (12) . Thus, our observations unravel a previously undescribed mechanism through which RARα-PLZF can cause differentiation arrest and favor proliferation, by inhibiting C/EBPα activity.
PLZF has been shown to control myelopoiesis via binding to C/EBPA promoter, resulting in a two-fold decrease in C/EBPA mRNA levels (32) . In contrast, RARα-PLZF does not affect C/EBPα levels as shown here by RT-PCR and quantitative Western blotting, possibly due to fusion with the RARα moiety as discussed above. Rather, we show that both PLZF and RARα-PLZF bind C/EBPα, and therefore, both can repress myeloid gene expression via direct protein-protein interactions and recruitment of corepressors, without binding DNA. Because the pool of stem cells and progenitors remains balanced despite the production of large numbers of differentiated myeloid cells during steady state and in stress response, we propose that the regulation of gene expression programs by protein-protein interactions provides an additional level of complexity that modifies the outcome of protein-DNA interactions and that networks of interacting transcriptional regulators can keep the hematopoietic system stable despite peripheral fluctuations.
The t(11;17) APL is mostly of poor prognosis, and the disease is relatively RA-resistant, possibly due to RA-resistant corepressor recruitment (33) and/or CRABPI derepression (16) . Additionally, the inhibition of C/EBPe by PLZF-RARα (34) and the inhibition of C/EBPα by RARα-PLZF reported here, both required for terminal granulocytic differentiation, unequivocally contribute to this RA resistance and support the use of HDAC inhibitors for the treatment of t(11;17) APL. Furthermore, the presence of RARα-PLZF could facilitate leukemogenesis by eliminating the need for additional hits such as the deletion of the remaining Plzf allele that could dysregulate the control of cell proliferation and myeloid differentiation. Thus, in PLZF-RARα transgenic mice, loss of wild-type Plzf was sufficient to modify a CML-like disease into APL (12) , in lieu of the coexpression of RARα-PLZF. The extensive network of protein-protein interaction entertained by both fusion proteins and the functional contribution of these fusion proteins to cell transformation could explain the fact that the incidence of APL does not increase with age, consistent with one or a limited number of rate-limiting mutation(s) (1, 35) . Fig. 3B with antibodies against acetylated histone H3 or a control rabbit IgG. (G) TSA restores Csf3r expression in RARα-PLZF expressing cells. Cells were exposed or not to TSA (10 ng/mL) for 6 h. Csf3r mRNA levels, assessed by RT-PCR (as in Fig.  1E ), in untreated cells were set as 1 after normalization to S16 levels (n = 2). (H) A model of repression of C/EBPα target genes by RARα-PLZF. RARα-PLZF is recruited on C/EBP consensus sequences by its ability to physically interact with C/EBPα, resulting in HDAC1 recruitment, histone H3 hypoacetylation, and decreased expression of C/EBPα target genes.
